IMM 47
Alternative Names: IMM-47Latest Information Update: 11 Oct 2023
At a glance
- Originator ImmuneOnco Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD24 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Aug 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in Australia (IV) (NCT05985083)
- 04 Aug 2023 ImmuneOnco Biopharmaceuticals in collaboration with IQVIA RDS plans a phase I trial for Solid tumours (Late stage disease, Second line therapy or greater) in Australia (NCT05985083)
- 20 Jul 2023 ImmuneOnco Biopharma plans a clinical trial for Solid tumours in mid-2023 (ImmuneOnco Biopharma pipeline, July 2023)